Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension

Drugs & Aging
J C Adkins, J A Balfour

Abstract

Brimonidine is a highly selective alpha 2-adrenoceptor agonist which reduces intraocular pressure (IOP) by reducing aqueous humour production and increasing aqueous humour outflow via the uveoscleral pathway. Brimonidine is indicated for the topical management of open-angle glaucoma or ocular hypertension. In 3 large comparative studies in patients with open-angle glaucoma or ocular hypertension, the ocular hypotensive efficacy of brimonidine was maintained during treatment periods of up to 1 year. Mean reductions in peak (measured 2 hours after the morning dose) and trough (measured 12 hours after the evening dose) IOP were 5.6 to 5.9 and 3.3 to 3.7 mm Hg, respectively, after 3 or 12 months of treatment with brimonidine 0.2% twice daily. The efficacy of brimonidine in this setting was similar to that of timolol 0.5% twice daily at peak only (-6.0mm Hg), and superior to that of betaxolol 0.25% twice daily at both peak (-3.5mm Hg) and trough (-2.7mm Hg). When added to topical beta-adrenoceptor antagonist therapy, initial results showed brimonidine 0.2% twice daily to have additive ocular hypotensive efficacy similar to that of pilocarpine 2% 3 times daily. Thus, brimonidine 0.2% may be a useful adjunct in this setting. According...Continue Reading

Citations

May 3, 2000·Seminars in Ophthalmology·J W Doyle, M F Smith
Jul 5, 2001·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·C P Jonescu-CuypersB Martin
Oct 23, 2002·Acta Ophthalmologica Scandinavica. Supplement·L TavernitiUNKNOWN Donati
Apr 17, 2008·Clinical & Experimental Ophthalmology·Seng Chee LoonJonathan C Craig
Oct 1, 2009·Clinical & Experimental Ophthalmology·Nitza Goldenberg-CohenDov Weinberger
Oct 1, 2014·Expert Opinion on Pharmacotherapy·Sky K ChewIvan Goldberg
May 26, 2017·Neurodegenerative Disease Management·Gurjeet JutleyM Francesca Cordeiro
May 16, 2018·Journal of Glaucoma·Tomas Bro, Christina Lindén
Nov 9, 2018·Expert Opinion on Pharmacotherapy·Daniel J OhMark S Dikopf
Mar 18, 2003·Current Opinion in Pediatrics·Lori Prok, Dan Hall
Jul 3, 2015·Drugs & Aging·David C Broadway, Heidi Cate
Aug 6, 2014·Expert Review of Clinical Pharmacology·Lana X Tong, Angela Yen Moore
Apr 30, 2020·Human & Experimental Toxicology·N Cimolai
Aug 19, 2020·Clinical & Experimental Optometry : Journal of the Australian Optometrical Association·Jack PhuMichael Kalloniatis
Mar 20, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Andrew A AcheampongDiane Tang-Liu
Apr 30, 2004·Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·Ullrich HoffmannJohannes P Haas
Oct 28, 2003·The Journal of Dermatology·Punita Kumari SodhiJohn Ratan
Aug 8, 2001·Journal of Cataract and Refractive Surgery·Z Z NagyI Süveges
Sep 19, 2007·Pediatric Emergency Care·Enrique Soto-Pérez-de-CelisBeatriz Guzmán Cisneros
Nov 11, 2009·Current Eye Research·Igor KaisermanShlomo Vinker
Jul 15, 2015·Journal of Glaucoma·Ralph PinheiroR Michael Dutescu
Feb 21, 2018·Optometry and Vision Science : Official Publication of the American Academy of Optometry·Eugene McLaurinJoseph B Ciolino
Dec 14, 2018·Clinical & Experimental Optometry : Journal of the Australian Optometrical Association·Stacey L AckermanJason L Vittitow
Feb 26, 2019·Pharmaceutical Research·Mihir ShahVeena Viswanath
Feb 28, 2020·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Fikret Ucar, Servet Cetinkaya
Apr 2, 2020·Expert Opinion on Pharmacotherapy·Lindsay MachenJonathan S Myers
Jan 1, 2012·Ophthalmology and Eye Diseases·Laura CrawleyLi Guo
May 10, 2017·Expert Opinion on Pharmacotherapy·Mark S DikopfDeepak P Edward
Dec 12, 2018·European Journal of Ophthalmology·Constantine D GeorgakopoulosOlga E Makri
Mar 9, 2021·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Fikret Ucar, Servet Cetinkaya
Nov 1, 2020·Ceská a slovenská oftalmologie : casopis Ceské oftalmologické spolecnosti a Slovenské oftalmologické spolecnosti·J LeštákK Marešová
Apr 29, 2011·Experimental Eye Research·Stella Arthur, Louis B Cantor
Jun 1, 2021·Journal of Ophthalmology·Dong Hyun KimJeong-Min Hwang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.